D-mannose is being increasingly used as an effective alternative to antibiotics for various conditions. A simple sugar, d-mannose is found naturally in high amounts in many fruits such as apples, oranges, and peaches, as well as blueberries and cranberries. Vegetables, including green beans, cabbage, and broccoli, are also a common source. In addition, d-mannose occurs naturally in some cells in the human body and is thought to be a prebiotic, because consumption of d-mannose stimulates and fosters the growth of good bacteria in the digestive tract.
Chemically, d-mannose is considered a simple sugar. Structurally, it is similar to glucose, but it is absorbed more slowly in the gastrointestinal tract. This accounts for its lower glycemic index. Compared with actual glucose, which is readily absorbed and has a glycemic index of 100, mannose must first be converted into fructose and then into glucose, significantly blunting the insulin response and reducing its impact on blood sugar levels. After mannose is absorbed by the gut, it is not stored in the liver like glucose but is filtered out of the body directly by the kidneys.
Mannose is of interest to health researchers for its possible use in a variety of conditions. One of these is its potential application as an early marker of impaired glucose tolerance. In a study of 273 subjects with and without diabetes that investigated the relationship between fasting plasma mannose levels and fasting plasma glucose levels,1 mannose absorption showed a relatively flat post-ingestion curve, compared with glucose, with less variability throughout the day. The fluctuations were, however, very closely correlated, suggesting the possibility that mannose might be used to detect alterations in glucose metabolism earlier than is currently possible.
Perhaps the most promising use for d-mannose is as an anti-infective agent. Most research to date has been done in the area of urinary tract infection (UTI), specifically in women. This common complaint accounts for nearly 8 million visits to a healthcare office and 1.5 million trips to an emergency department each year, at a cost of more than $3.5 billion in the United States.2
In addition, there are a growing number of reports that document microbial resistance to traditional antibiotics, increasing both the cost and morbidity of this complaint.3 A study of nearly 200 female college students presenting with symptoms of UTI found that more than 40% of infections were resistant to first- and second-line antibiotics.3
This article originally appeared on Clinical Advisor